Lynne Fahey Mcgrath net worth and biography

Lynne Mcgrath Biography and Net Worth

Director of Alzamend Neuro

Lynne Mcgrath is the Director of Alzamend Neuro.

What is Lynne Fahey Mcgrath's net worth?: The estimated net worth of Lynne Fahey Mcgrath is at least $34.15 as of October 23rd, 2025. Mcgrath owns 25 shares of Alzamend Neuro stock worth more than $34 as of October 7th. This net worth estimate does not reflect any other investments that Mcgrath may own. Learn More about Lynne Fahey Mcgrath's net worth.
How do I contact Lynne Fahey Mcgrath?: The corporate mailing address for Mcgrath and other Alzamend Neuro executives is 480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA, 30326. Alzamend Neuro can also be reached via phone at (844) 722-6333. Learn More on Lynne Fahey Mcgrath's contact information.
Has Lynne Fahey Mcgrath been buying or selling shares of Alzamend Neuro?: Lynne Fahey Mcgrath has not been actively trading shares of Alzamend Neuro within the last three months. Most recently, Lynne Fahey Mcgrath sold 30 shares of the business's stock in a transaction on Thursday, October 23rd. The shares were sold at an average price of $2.29, for a transaction totalling $68.70. Following the completion of the sale, the director now directly owns 25 shares of the company's stock, valued at $57.25. Learn More on Lynne Fahey Mcgrath's trading history.
Who are Alzamend Neuro's active insiders?: Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), William Horne (Director), Lynne Mcgrath (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.
Are insiders buying or selling shares of Alzamend Neuro?: During the last year, Alzamend Neuro insiders bought shares 1 times. They purchased a total of 108,388 shares worth more than $108,388.00. During the last year, insiders at the sold shares 7 times. They sold a total of 186,384 shares worth more than $451,682.34. The most recent insider tranaction occured on August, 26th when Director Milton C. Ault III sold 2,000 shares worth more than $3,120.00. Insiders at Alzamend Neuro own 1.4% of the company. Learn More about insider trades at Alzamend Neuro.
Information on this page was last updated on 8/26/2026.

Lynne Fahey Mcgrath Insider Trading History at Alzamend Neuro

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/23/2025	Sell	30	$2.29	$68.70	25
3/22/2023	Buy	7	$580.50	$4,063.50	7

Lynne Fahey Mcgrath Buying and Selling Activity at Alzamend Neuro

Alzamend Neuro Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $1.37

$1.34

$1.42

50 Day Range

MA: $1.61

$1.31

$1.94

2 Week Range

Now: $1.37

$0.84

$2.68

Volume

18,195 shs

Average Volume

126,001 shs

Market Capitalization

$6.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27